These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32668706)

  • 1. The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment.
    Langley PC
    Pharmacy (Basel); 2020 Jul; 8(3):. PubMed ID: 32668706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22.
    Langley P
    F1000Res; 2022; 11():248. PubMed ID: 35444797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.
    Langley PC
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Information or Evidence? Abandoning Imaginary Worlds for Blockchains in Health Technology Assessment.
    Langley PC
    Innov Pharm; 2018; 9(3):1-5. PubMed ID: 34007719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facilitating bias in cost-effectiveness analysis: CHEERS 2022 and the creation of assumption-driven imaginary value claims in health technology assessment.
    Langley P
    F1000Res; 2022; 11():993. PubMed ID: 36226039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.
    Langley PC
    Innov Pharm; 2021; 12(3):. PubMed ID: 35601587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies.
    Langley PC
    Innov Pharm; 2019; 10(3):. PubMed ID: 34007563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
    Langley PC
    Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement, modeling and QALYs.
    Langley PC; McKenna SP
    F1000Res; 2020; 9():1048. PubMed ID: 33093950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy.
    Langley PC
    Innov Pharm; 2019; 10(3):. PubMed ID: 34007562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2018; 9(4):. PubMed ID: 34007726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds.
    Langley PC
    Innov Pharm; 2018; 9(2):1-5. PubMed ID: 34007702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More Unnecessary Imaginary Worlds - Part 3: Cystic Fibrosis and the Institute for Clinical and Economic Review's Draft Evidence Report.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.